Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 9.91 is 40% above its 5-year average of 7.08, near the high end of its 5-year range (3.36–10.81).
As of the fiscal period ended Tuesday, June 30, 2026. 5.65% above its 12-month average of 9.38.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.91.
QUICK RATIO (ACID-TEST)
9.91
QUICK RATIO (ACID-TEST) AVG TTM
9.38
QUICK RATIO (ACID-TEST) AVG 3Y
8.25
QUICK RATIO (ACID-TEST) AVG 5Y
7.08
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.65%
CURRENT VS 3Y AVG
+20.14%
CURRENT VS 5Y AVG
+39.99%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+195.80%
vs the sector median at left
Kymera Therapeutics, Inc.
Market Cap
$8.61B
Quick Ratio (Acid-Test)
9.91
TTM Avg
9.38
3Y Avg
8.25
5Y Avg
7.08
Market Cap
$8.63B
Quick Ratio (Acid-Test)
5.90
TTM Avg
5.80
3Y Avg
4.66
5Y Avg
4.84
Market Cap
$8.39B
Quick Ratio (Acid-Test)
1.08
TTM Avg
0.93
3Y Avg
1.08
5Y Avg
1.24
Market Cap
$8.88B
Quick Ratio (Acid-Test)
21.71
TTM Avg
12.60
3Y Avg
12.43
5Y Avg
10.88
Market Cap
$8.95B
Quick Ratio (Acid-Test)
0.92
TTM Avg
0.82
3Y Avg
1.02
5Y Avg
1.25
Market Cap
$8.96B
Quick Ratio (Acid-Test)
1.34
TTM Avg
1.76
3Y Avg
2.38
5Y Avg
3.52
Market Cap
$9.20B
Quick Ratio (Acid-Test)
0.92
TTM Avg
0.82
3Y Avg
1.02
5Y Avg
1.25
Market Cap
$7.95B
Quick Ratio (Acid-Test)
3.72
TTM Avg
4.16
3Y Avg
4.17
5Y Avg
4.79
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.61B | 9.91 | 9.38 | 8.25 | 7.08 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.63B | 5.90 | 5.80 | 4.66 | 4.84 |
| Oscar Health, Inc. (OSCR)vs › | $8.39B | 1.08 | 0.93 | 1.08 | 1.24 |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.88B | 21.71 | 12.60 | 12.43 | 10.88 |
| Bruker Corporation (BRKRP)vs › | $8.95B | 0.92 | 0.82 | 1.02 | 1.25 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.96B | 1.34 | 1.76 | 2.38 | 3.52 |
| Bruker Corporation (BRKR)vs › | $9.20B | 0.92 | 0.82 | 1.02 | 1.25 |
| TG Therapeutics, Inc. (TGTX)vs › | $7.95B | 3.72 | 4.16 | 4.17 | 4.79 |
| Insulet Corp. (PODD)vs › | $9.31B | 1.83 | 2.42 | 2.51 | 3.28 |
| Caris Life Sciences, Inc. (CAI)vs › | $7.75B | 4.88 | 4.46 | 3.60 | 3.01 |
Quick Ratio
9.91
Excludes inventory
Current Ratio
9.83
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 9.91 |
| 2026-03-31 | 10.81 |
| 2025-12-31 | 10.47 |
| 2025-09-30 | 7.38 |
| 2025-06-30 | 8.32 |
| 2025-03-31 | 8.49 |
| 2024-12-31 | 7.53 |
| 2024-09-30 | 8.55 |
| 2024-06-30 | 8.45 |
| 2024-03-31 | 9.57 |
| 2023-12-31 | 4.73 |
| 2023-09-30 | 5.95 |
| 2023-06-30 | 7.06 |
| 2023-03-31 | 6.65 |
| 2022-12-31 | 5.88 |
| 2022-09-30 | 5.42 |
| 2022-06-30 | 4.60 |
| 2022-03-31 | 4.88 |
| 2021-12-31 | 4.88 |
| 2021-09-30 | 5.75 |
| 2021-06-30 | 3.36 |
| 2021-03-31 | 3.09 |
| 2020-12-31 | 2.73 |
| 2020-09-30 | 2.77 |
| 2020-06-30 | 3.71 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 2.69 |
| 2019-09-30 | 0.00 |
